Primary squamous cell carcinoma of the prostate: a case report of a rare clinical entity

Primary squamous cell carcinoma of the prostate is a unique and rare clinicopathological entity with fewer than 100 cases reported in the literature. Because of its rarity, the optimal management is not well known. Here, we report a case of primary squamous cell carcinoma of the prostate which was treated with definitive concurrent chemo-radiotherapy with excellent outcome along with a brief review of the literature.

This is a case report about a rare form of prostate cancer called squamous cell cancer. It behaves more aggressively compared with more common types of prostate cancer. The treatment is controversial due to its rarity, but is different than that of the common variety of prostate cancer. From available limited information, it can be treated either with combined chemotherapy and radiotherapy or radical surgery for early stage disease.

Keywords: chemo-radiation • squamous cell carcinoma of prostate

Initial diagnosis
In June of 2011, the patient underwent laser transurethral resection of prostate for presumed benign prostatic hypertrophy. The tissue was not sent for histological examination. While his urinary symptoms were improved, he developed increasing anorectal discomfort along with lower back pain and bright red blood per rectum. He underwent an abdominal and pelvic CT scan on 8 July 2011, which showed enlarged prostate gland with indistinct borders merged imperceptibly with the rectum. He underwent an endoscopic ultrasound which showed a hypo-echoic mass deep to the bowel, appeared originating from the prostate gland and extending into the wall of the rectum. His initial prostate-specific antigen (PSA) on 16 August 2011 at diagnosis was normal at 1.2 ng/ml.

A staging positron emission tomography PET-CT scan (Figure 1B – axial and coronal views) was performed, which revealed a hypermetabolic large prostate mass with likely invasion of the rectum. On the CT scan (Figure 1C), the rectum was clearly seen separate from the prostate tumor and being pushed by this mass. A regional hypermetabolic lymph node was also seen on the PET-CT scan. Therefore, he was staged as T4N1M0.

Treatment
He was evaluated by the surgeon, and given the locally advanced nature of his malignancy, he was recommended neoadjuvant therapy followed by most likely pelvic exenteration. The patient underwent chemo-radiation concurrently. His chemotherapy regimen included Mitomycin C and 5-Fluoro-uracil.
Biswas, Podder, Lepera & Walker

(5FU) intravenous continuous infusion every 3 weeks for two cycles. He received pelvic radiotherapy with 45 Gray (Gy) in 25 fractions and an additional 9 Gy boost to the gross tumor to a total dose of 54 Gy.

Outcome

Following completion of his therapy, he underwent a repeat PET-CT scan (Figure 2A), and CT scans (Figure 2B), MRI scans (Figure 2C), which showed complete metabolic response and no obvious tumor on CT and MRI scans. He underwent examination under anaesthesia (EUA) and biopsy (Figure 2D). The pathology confirmed benign prostatic gland and no malignant tumor cells. On his last followup on 17 January 2014, which is 27 months later, the patient is doing well without any evidence of local or distant recurrence based on a repeated PET-CT scan.

Discussion

Carcinoma of the prostate gland is an extremely rare malignancy accounting for less than 0.5–1% of all prostate carcinomas. The first case was described in 1926, and to date, about 77 cases have been reported including the current case [1]. The mean age at presentation is 59 years (range 52–79 years), [2] and our patient was 57 years old at the time of presentation. It is thought to be rather aggressive with an average survival of 14 months [1]. The pathogenesis of SCC is not fully understood. There have been case reports of secondary SCC of prostate following radiation treatment of more common adenocarcinoma of the prostate [3]. The cell of origin is also debatable. Some have thought the origin of this rare malignancy of prostate is the prostatic urethral mucosa, while others have concluded that it arises from the transitional epithelium of periurethral ducts or the basal cells of prostatic acini [4,5]. There is no specific immunohistochemical marker for this rare but aggressive malignancy. Lager et al. have postulated that SCC of prostate develops due to adverse stimuli affecting columnar cells and they lose their ability to secrete PSA and prostatic acid phosphatase but ability to produce keratin [6]. Inability to secrete PSA suggests most likely separate pathogenesis of this cancer and less likelihood to respond to standard androgen blockade.
that is done in prostate adenocarcinoma. Clinically, it may be indistinguishable from more common counterpart adenocarcinoma of the prostate with presenting symptoms being urinary obstruction or pain secondary to bony metastasis, although the natural history is much different. It does not produce PSA. From the available limited case reports with complete information about treatment and outcome (Table 1), it appears that SCC of prostate can fail both locoregionally including pelvic lymph nodes but also distant sites including bones, liver and lungs. The bony lesions are usually osteolytic rather than osteoblastic seen in adenocarcinoma of prostate. Therefore, histological diagnosis is crucial with appropriate immunohistochemistry when appropriate to exclude more common adenocarcinoma subtype. In our patient, his initial transurethral resection of prostate tissue was not sent for histological diagnosis and the biopsy from his rectum showing squamous cell histology which initially was thought to be originating from anus. The subsequent imaging studies confirmed the primary site of origin to be prostate gland.

Because of the rarity of this malignancy, the treatment is controversial. From the limited case reports with complete information about treatment and outcome that are available in English literature, it appears that more aggressive therapy including surgery, or combined radiation and chemotherapy provides best outcome (Table 1) for organ confined disease. Because of distinguished pathogenesis, routine androgen blockade using orchietomy should not be considered in palliative setting [7–13].

Figure 2. Post-treatment imaging studies and biopsy result. (A) Post-treatment positron emission tomography-CT scan showing complete metabolic response following completion of therapy. (B & C) Post-treatment CT and MRI scan showing excellent response (green arrow) to therapy with rectum in normal position (red arrow). (D) Post-treatment biopsy showing no malignant cells present (low power microscopy).
Of particular interest is the report by Munoz et al. [1]. They reported an encouraging result of treating with concurrent chemo-radiotherapy using cisplatin and 5FU, similar to the regimen used in SCC of anal origin. The patient remained disease free for 5 years when he relapsed locally and died. Similar to this, Majeed et al., Okada et al., Uchibayashi et al. and the current case showed greater than 15 months survival without any evidence of recurrence with combined chemo-radiotherapy. Our patient received similar chemotherapy regimen as anal cancer with excellent response. Few other reports with aggressive radical surgery with cysto-prostatectomy with or without chemotherapy suggested similar survival as well for organ confined disease.

Our patient was planned to undergo pelvic exenteration after completing neoadjuvant chemo-radiotherapy. However, his post-treatment PET-scan and MRI scan showed complete metabolic response and very nice radiographic response, respectively. In addition, he underwent examination under anaesthesia (EUA) with biopsy showing benign prostate tissue but no malignancy (Figure 2D).

This patient received concurrent chemo-radiotherapy utilizing Mitomycin C and 5FU iv. continuous infusion, the regimen commonly used in anal

---

**Table 1. Selected case reports with complete information about treatment and outcome that are available in the English literature.**

| Study          | Age (years) | Sites of metastasis         | Treatment; Surgery                        | Modality; Chemo-RT           | Survival (months) | Ref. |
|----------------|-------------|-----------------------------|-------------------------------------------|------------------------------|-------------------|------|
| Mott IJ (two patients) | 59, 65      | Bone, osteolytic           | Orchietomy                                | DES, chemo, palliative XRT  | 5, 8              | [7]  |
| Sharma DP      | 69          | Local, liver, lung         | Pelvic exenteration, pelvic/inguinal lymphadenectomy | XRT, mitoxantrone, cisplatin | 6                | [8]  |
| Majeed F       | 71          | None                       | Radical prostatectomy                     | XRT, mitoxantrone, cisplatin | 18+              | [9]  |
| Okada E        | 65          | Iliac lymph nodes          | XRT, PEP, cisplatin                      | XRT, PEP, cisplatin          | 18+              | [10] |
| Uchibayashi T  | 72          | None                       | XRT, bleomycin, cisplatin                | XRT, bleomycin, cisplatin    | 21+              | [11] |
| Imamura M      | 54          | Local                      | Radical cystoprostatectomy               | Methotrexate, peplomycin, cisplatin | 60 +          | [12] |
| Munoz F        | 76          | Pelvic                     | Radical prostatectomy                     | Methotrexate, 5FU, XRT       | 60               | [1]  |
| Sharma SK      | 65          | None                       | Orchietomy                                | 0                            | [13]             |
| Di Pietro C    | 72          | Iliac lymph nodes, liver   | TURP                                      | 0                            | [14]             |
| Moskovitz B    | 65          | Lung                       | Radical prostatectomy, TURP              | 5                            | [15]             |
| Ulloa SA       | 83          | Lung                       | TURP                                      | 13                           | [16]             |
| Little NA      | 56, 55      | Pelvic lymph nodes and lung, none | Radical cystoprostatectomy               | 25, 40+                      | [17]             |
| Nabi G (two patients) | 60, 72     | Osteolytic bone and lung and liver; bone and lung | Palliative XRT, adriamycin, methotrexate, folinic acid | 4, 5                     | [2]  |
| Gray G         | 65          | Regional in perineum       | TURP, APR                                 | 12                           | [18]             |
| Corder MP      | 67          | Nodes                      | XRT, chemo                                | 5                            | [19]             |
| Kantham R (six patients) | 42–85      | Lungs, bone                | TURP (3)                                  | XRT (1), chemotherapy (4)    | 1–13             | [20] |
| Malik RD       | 77          | Pelvic Lymph nodes, lung   | Pall. XRT                                 | 3                            | [5]              |
| Present case   | 58          | None                       | None                                      | XRT, 5FU, mitomycin C        | 27+              | -    |

SFU: 5-Fluoro-uracil; APR: Anterior pelvic resection; DES: Diethyl stilbestrol; PALL: Palliative; PEP: Peplomycin; TURP: transurethral resection of prostate; XRT: External bradiotherapy.
Primary squamous cell carcinoma of the prostate

Case Report

Primary SCC is a rare but distinct clinicopathological entity with rather aggressive natural course. From anecdotal case reports, it appears aggressive local therapy with concurrent chemo-radiation is a reasonable treatment option with encouraging survival for organ confined disease. Radical surgery can be utilized either as a primary approach or as a salvage therapy for local recurrence. The chemotherapy regimen commonly used and can be used, are the ones used for SCC of other anatomical sites like anal cancer or head and neck cancer.

Conclusion

Primary SCC is a rare cancer with limited knowledge. With improvement in our understanding, along with better imaging and better histological diagnosis, we will better recognize this entity as a complete separate disease from the common adenocarcinoma of the prostate. Even though it will be extremely unlikely that there will be a study comparing different treatment modalities, with many case reports, we will continue to refine the treatment recommendation.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Informed consent disclosure

The authors state that they have obtained informed consent from the patient for the inclusion of their medical and treatment recommendation.

Open Access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Executive summary

- Primary de novo squamous cell carcinoma of the prostate is an extremely rare entity.
- Only fewer than 100 case reports have been published in the literature.
- Here, we report a case with primary squamous cell carcinoma of the prostate with brief discussion on review of literature.

References

Papers of special note have been highlighted as: • of interest

1. Munoz F, Franco P, Ciambella P et al. Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat. Oncol. 2, 15–21 (2007).
2. Nabi G, Ansari MS, Singh I, Sharma MC, Dogra PN. Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity. Report of 2 cases and review of literature. Urol. Int. 66, 216–219 (2001).
3. Arva NC, Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn. Pathol. 6, 46–53 (2011).
4. Wernert N, Geobbles R, Bonkhoff H, Dhom G. Squamous cell carcinoma of the prostate. Histopathology 17, 339–344 (1990).
5. Malik RD, Dakwar G, Hardee ME et al. Squamous cell carcinoma of the prostate. Rev. Urology 13, 56–60 (2011).
6. Lager DJ, Goeken JA, Kemp JD, Robinson RA. Squamous metaplasia of the prostate: An immunohistochemical study. Am. J. Clin. Pathol. 90, 597–601 (1988).
7. Mott LJ. Squamous cell carcinoma of the prostate. Report of 2 cases and review of the literature. J. Urol. 121, 833–835 (1979).
8. Sarma DP, Weilbaecher TG, Moon TD. Squamous cell carcinoma of the prostate. Urology 27, 260–262 (1991).
9. Majeed F, Javed TA, Khan AU, Koerber RK. Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen. J. Urol. 168, 640 (2002).
10. Okada E, Kamizaki H. Primary squamous cell carcinoma of the prostate. Int. J. Urol. 7, 347–350 (2000).
Case Report

Biswa, Podder, Lepera & Walker

11 Uchibayashi T, Hisazumi H, Hasegawa M et al. Squamous cell carcinoma of the prostate. *Scand. J. Urol. Nephrol.* 31, 223–224 (1997).

12 Imamura M, Nishiya H, Ohmori K, Nishimura K. Squamous cell carcinoma of the prostate without evidence of recurrence 5 years after operation. *Urol. Int.* 65, 122–124 (2000).

13 Sharma SK, Malik AK, Bapna BC. Squamous cell carcinoma of prostate. *Indian J. Cancer* 17, 134–135 (1980).

14 Di Pietro C, Celia A, De Stefani S et al. Squamous cell carcinoma of the prostate. *Arch. Ital. Urol. Androl.* 78, 75–76 (2006).

15 Moskovitz B, Munichor M, Bolkier M, Livne PM. Squamous cell carcinoma of the prostate. *Urol. Int.* 51, 181–183 (1993).

16 Ulloa SA, Iturregui JR, Amezquita M, Ortiz VN. Squamous cell carcinoma of the prostate: case report and review of literature. *Bol. Assoc. Med. P R* 89, 192–194 (1997).

17 Little NA, Wiener JS, Walther PJ, Paulson DF, Anderson EE. Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature. *J. Urol.* 149, 137–139 (1993).

18 Gray GF Jr, Marshall VF. Squamous carcinoma of the prostate. *J. Urol.* 113, 736–738 (1975).

19 Corder MP, Cicmil GA. Effective treatment of metastatic squamous cell carcinoma of the prostate with adriamycin. *J. Urol.* 115, 222 (1976).

20 Kanthan R, Torkian B. Squamous cell carcinoma of the prostate. A report of 6 cases. *Urol. Int.* 72, 28–31 (2004).